Pharmacogenomics-Supported Psychotropic Prescribing Trial
Launched by UNIVERSITY OF MANITOBA · Apr 14, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Pharmacogenomics-Supported Psychotropic Prescribing Trial is a study designed to explore how genetic testing can help doctors choose the best medications for adults experiencing mental health issues. Specifically, this trial aims to see if testing a person's genes can guide the safe and effective use of psychiatric medications for those admitted to psychiatric units in Manitoba. The study is not yet recruiting participants, but when it starts, it will focus on adults aged 18 and older who may need changes to their medication.
To be eligible for this trial, participants must be currently receiving care in an inpatient setting and have a doctor who believes that genetic testing could help improve their treatment. Participants will need to provide a saliva sample for the genetic analysis. If someone has already had this testing done or has certain medical histories, they may not qualify. This study could potentially lead to better personalized treatment options for mental health patients, helping to reduce side effects and improve overall care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Presented for services within inpatient units in Manitoba
- • Aged 18 years or older
- • The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated
- • The treating clinician thinks PGx testing can benefit and refers the patient to the study
- Exclusion Criteria:
- • Unwillingness to donate saliva samples for genetic analysis
- • History of liver or bone marrow (hematopoietic cell) transplantation
- • PGx testing results are already available
- • No personal health identification number (PHIN) is available
About University Of Manitoba
The University of Manitoba, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive expertise in medical research, public health, and community engagement to conduct rigorous and ethical clinical studies. The institution aims to translate scientific findings into practical applications that enhance patient care and improve health outcomes. Committed to fostering a culture of excellence and integrity, the University of Manitoba prioritizes participant safety and scientific validity in all its clinical research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winnipeg, Manitoba, Canada
Winnipeg, Manitoba, Canada
Patients applied
Trial Officials
Abdullah Al Maruf, PhD, M.Pharm., B.Pharm
Principal Investigator
University of Manitoba
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported